Research Article

Course of Hyperkalemia in Patients on Hemodialysis

Table 3

Dialysis adequacy and prescription parameters in placebo patients (n = 86).

DayspKt/VUrea removal rate (%)Dialysate flow (mL/min)Dialysate potassium concentration (mmol/L)Prescribed ultrafiltration rate (mL)Blood flow (mL/min)

−71.71 (0.38)74.3 (5.8)548.0 (131.1)2.24 (0.46)2785.8 (1228.1)321.0 (95.8)
11.99 (0.85)73.3 (6.4)545.3 (133.7)2.23 (0.48)2753.0 (1197.1)316.0 (95.8)
32.24 (0.48)
52.23 (0.48)
82.22 (0.47)
122.22 (0.47)
152.24 (0.48)
222.26 (0.57)
291.67 (0.35)72.3 (7.1)545.9 (143.3)2.21 (0.47)2807.6 (1176.5)317.3 (95.0)
362.22 (0.47)
432.22 (0.48)
502.22 (0.48)
571.70 (0.43)73.6 (5.4)548.7 (130.4)2.24 (0.46)2843.0 (1098.3)320.7 (98.8)

Data are mean (standard deviation). Data are shown for the 86 placebo patients with predialysis sK+ measurements at randomization (visit 4, day 1). sK+, serum potassium; spKt/V, target single pool Kt/V.